Videos

The senior researcher at Seattle Children’s discussed advantages of engineered Tregs compared with natural Tregs.

The associate professor of neurology at the Cleveland Clinic Lerner Institute pointed out that genetic forms of PD may be the best place to start for new therapeutic research.

The professor in residence for pediatrics at the Sickle Cell Center of Excellence at the University of California discussed gene therapy’s ongoing transformation of the treatment landscape.

The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison emphasized similar variables in the way of therapy uptake regardless of country.

The cofounder and chief executive officer of Kate Therapeutics discussed research that awarded him an Outstanding New Investigator at the ASGCT 2024 meeting.

The associate professor of medicine at University of Colorado discussed data in the primary relapsed LBCL setting.

The chief scientific officer of Precision for Medicine discussed unique difficulties of designing clinical trials for PD gene therapy candidates.

The professor from Cedars Sinai discussed further research being conducted in the field after lifileucel’s approval.

The head of research at Mass General Brigham’s Cell and Gene Therapy Institute discussed work the center is engaged in with cell and gene therapy.

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC discussed her learning experience administering gene therapies for the first time.

The Senior Director and Head of Technology Development at Epic Bio discussed potential applications of the new technology.

The medical director of clinical development at AskBio discussed the progress of an early clinical trial of AB-1002.

The deputy director, Division of Rare Diseases Research Innovation, NCATS, NIH, discussed areas that the agency is targeting.

The scientist from Krembil Research Institute shared takeaways from the session she chaired.

The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.

The pediatric neurologist at Nemours Children’s Health discussed next steps in the field to fully enable the benefits of gene therapy.

The lead scientist at Percheron Therapeutics discussed research on antisense oligonucleotide therapies in mouse models of DMD.

The cofounder and chief scientific officer at Earli discussed the company’s unique approach to cancer diagnosis.

The director of the Mount Sinai Fuster Heart Hospital discussed how artificial intelligence complements data-driven research.

The McCaw Endowed Chair of Muscular Dystrophy at University of Washington discussed the role the ASGCT plays in the field.

The chief of cardiology at Weill Cornell Medical College discussed the center’s increased focus on genetic research.

The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison shared highlights from the discussion.

The chief product officer at Mission Bio discussed the company’s Genome Editing Solution.

The professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center discussed the advantages the newly approved CAR-T has for older, frailer patients.

The associate professor of clinical pediatrics at Cincinnati Children's discussed further investigations into novel therapies and new research.

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed a sub analysis of the HOPE-B trial.

The assistant professor at Moffit Cancer Center discussed the subgroup analysis she presented at ASCO’s 2024 Annual Meeting.

The Chief Medical Officer of Addimmune discussed the unmet need with HIV and research the company is conducting.